0214-3429

Revista Española de Quimioterapia

Sociedad Espanola de Quimioterapia

Health Score

0 Poor

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Deposit reference lists for 694 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact694 DOIs
2

Add license metadata to 694 records

License metadata tells indexers and readers how each article may be reused.

High impact694 DOIs
3

Attach ORCID iDs across 465 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact465 DOIs

DOIs for this ISSN

Showing the top 5 of 656 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Biomarkers of fungal infection: Expert opinion on the curren… (10.37201/req/2260.2019)
Abstract References ORCID License
149.14 30
2 Insights for COVID-19 in 2023 (10.37201/req/122.2022)
References ORCID License
139.75 72
3 Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3… (10.37201/req/002.2022)
References ORCID License
131.69 56
4 Aspiration pneumonia (10.37201/req/s01.17.2022)
References ORCID License
130.53 54
5 New variants of SARS-CoV-2 (10.37201/req/071.2021)
References ORCID License
129.93 53
6 Pharmacological treatment of COVID-19: an opinion paper (10.37201/req/158.2021)
References ORCID License
128.07 50
7 Chronic obstructive pulmonary disease (COPD) in Spain and th… (10.37201/req/2064.2019)
Abstract References ORCID License
127.88 18
8 Recommendations for use of antigenic tests in the diagnosis… (10.37201/req/120.2020)
References ORCID License
127.42 49
9 Recommendations for the diagnosis and treatment of Clostridi… (10.37201/req/2065.2020)
Abstract References ORCID License
125.53 17
10 Temporary hospitals in times of the COVID pandemic. An examp… (10.37201/req/041.2021)
References ORCID License
124.71 45
11 Recommendations on the use of azole antifungals in hematolog… (10.37201/req/013.2023)
References ORCID License
121.74 41
12 Monkeypox in humans: a new outbreak (10.37201/req/059.2022)
References ORCID License
120.15 39
13 COVID-19: Impact on prescribing and antimicrobial resistance (10.37201/req/s01.19.2021)
References ORCID License
115.81 34
14 Mechanism of action of cefiderocol (10.37201/req/s02.02.2022)
References ORCID License
113.89 32
15 Secondary infections in mechanically ventilated patients wit… (10.37201/req/031.2021)
References ORCID License
111.85 30
16 Impact of the COVID-19 pandemic on the mental health of the… (10.37201/req/018.2023)
References ORCID License
109.68 28
17 Post-COVID syndrome: A reflection and opinion paper (10.37201/req/023.2021)
References ORCID License
108.54 27
18 Ceftazidime-avibactam (10.37201/req/s01.11.2021)
References ORCID License
108.54 27
19 Antimicrobial resistance and One Health (10.37201/req/s03.09.2022)
References ORCID License
108.54 27
20 New definitions of susceptibility categories EUCAST 2019: cl… (10.37201/req/s03.18.2022)
References ORCID License
108.54 27
21 COVID-19 in Spanish and immigrant patients in a sanitary dis… (10.37201/req/041.2020)
Abstract References ORCID License
107.92 11
22 Unusual case report of skin infection by Paenibacillus timon… (10.37201/req/079.2019)
Abstract References ORCID License
107.92 11
23 Continuous infusion of antibiotics using elastomeric pumps i… (10.37201/req/122.2020)
References ORCID License
107.35 26
24 Cefiderocol, a new antibiotic against multidrug-resistant Gr… (10.37201/req/s01.12.2021)
References ORCID License
106.12 25
25 Streptococcus cristatus, an infrequent cause of bacteremia a… (10.37201/req/090.2022)
Abstract References ORCID License
104.14 10
26 Utility of lateral flow tests in SARS-CoV-2 infection monito… (10.37201/req/052.2020)
References ORCID License
103.52 23
27 Remdesivir, the antiviral hope against SARS-CoV-2 (10.37201/req/028.2020)
References ORCID License
102.13 22
28 Real-life use of remdesivir in hospitalized patients with CO… (10.37201/req/018.2021)
References ORCID License
100.68 21
29 Sexually transmitted infections in Spain: Current status (10.37201/req/038.2023)
References ORCID License
100.68 21
30 Latent tuberculosis infection: approach and therapeutic sche… (10.37201/req/s03.20.2022)
References ORCID License
100.68 21
31 Two cases of Prevotella oris causing serious pleuropulmonary… (10.37201/req/001.2023)
Abstract References ORCID License
100.00 9
32 High level of medication regimen complexity index correlate… (10.37201/req/097.2020)
References ORCID License
99.17 20
33 Dalbavancin (10.37201/req/s01.07.2021)
References ORCID License
99.17 20
34 Respiratory co-and superinfections in COVID-19 (10.37201/req/s01.20.2021)
References ORCID License
99.17 20
35 Current treatment of nosocomial pneumonia and ventilator-ass… (10.37201/req/s03.06.2022)
References ORCID License
99.17 20
36 Ceftazidime-avibactam (10.37201/req/s01.09.2022)
References ORCID License
97.58 19
37 Ceftolozane-tazobactam: When, how and why using it? (10.37201/req/s01.10.2021)
References ORCID License
97.58 19
38 Antiviral drugs against SARS-CoV-2 (10.37201/req/s03.03.2022)
References ORCID License
97.58 19
39 Status of Herpes Zoster and Herpes Zoster Vaccines in 2023:… (10.37201/req/004.2023)
References ORCID License
95.91 18
40 Joint infection due to Elizabethkingia miricola (10.37201/req/081.2019)
Abstract References ORCID License
95.42 8
41 Increase in methicillin-resistant and ciprofloxacin-suscepti… (10.37201/req/082.2019)
Abstract References ORCID License
95.42 8
42 Epidemiology and clinical of infections and colonizations ca… (10.37201/req/086.2019)
Abstract References ORCID License
95.42 8
43 Bacteremia caused by Eikenella corrodens in a patient with p… (10.37201/req/128.2022)
Abstract References ORCID License
95.42 8
44 The first 100 cases of COVID-19 in a Hospital in Madrid with… (10.37201/req/072.2020)
References ORCID License
94.15 17
45 Bioinformatics approaches to the study of antimicrobial resi… (10.37201/req/s01.04.2021)
References ORCID License
94.15 17
46 Cefiderocol (10.37201/req/s01.07.2022)
References ORCID License
94.15 17
47 Resistance to beta-lactams in Gram-negative bacilli: relevan… (10.37201/req/s02.01.2022)
References ORCID License
94.15 17
48 Is the universal population Hepatitis C virus screening a co… (10.37201/req/030.2020)
References ORCID License
92.28 16
49 A systematic literature review and expert consensus on risk… (10.37201/req/062.2022)
References ORCID License
92.28 16
50 Antimicrobial activity of ceftolozane-tazobactam against Ent… (10.37201/req/019.2021)
References ORCID License
90.31 15